The Doctor the Hospital Could Not Silence
Consider him for a second before the argument starts. Scrubs, stethoscope, the ordinary face of the person you want in the room when something has gone wrong. Not a brand. Not a protocol. A doctor. For most of modern life that picture was enough. You did not need to know his politics or his employer's payer mix. You needed to know he would try to keep you alive.
That bargain came under extraordinary strain in hospitals during COVID, and one of the most disturbing accounts of how comes from a Senate hearing convened by Senator Ron Johnson, written up on October 1, 2026, by A Midwestern Doctor under the title "How Hospitals Turned on Their Patients During COVID." The witness who makes the piece cohere is James Miller, a trauma surgeon. His testimony is not a statistical survey of American medicine and should not be treated as one. It is an account from inside one hospital system, reinforced at the hearing by patients, relatives, doctors and lawyers describing their own experiences. Taken as testimony rather than unquestioned fact, it is disturbing enough.
Miller testified that before the pandemic he was the top producer at Providence Regional Medical Center Everett, operating more, achieving strong outcomes with comparatively few complications, and bringing substantial revenue into the hospital. He also testified that he had already learned what could happen when a doctor challenged institutional practice. While serving as interim director of the trauma team and attempting to raise surgical standards, he says a nurse leader emailed staff saying they needed to "get Dr. Miller." According to Miller, eleven complaints followed in two weeks, including an accusation of racism arising from his waving hello to a maintenance worker in a hallway. He also described a medical culture in which, in his view, institutional definitions of competence were becoming detached from practical surgical ability. These are Miller's allegations and recollections, not independently established findings, but they provide the background against which he interpreted what happened during COVID.
In January 2020, Providence Regional Medical Center Everett admitted the first confirmed COVID-19 patient in the United States. Remdesivir was used there extraordinarily early; Providence has itself described the case as the first use of the drug for COVID-19. The drug subsequently became a major part of the American treatment response. Miller, however, testified that he became deeply sceptical of it. He described bringing the infectious-disease service a young trauma patient whom he regarded as an obvious candidate, only to be told by the physician on call not to give it to her because she "seemed like a nice girl." If Miller's recollection is accurate, the remark deserves explanation.
The scientific history of remdesivir is more complicated than simply saying that it "did not work." The NIH-sponsored ACTT trial reported in 2020 that remdesivir significantly shortened recovery time in hospitalised COVID patients, although the magnitude and clinical importance of its benefits, particularly its effect on mortality, remained disputed as further evidence accumulated. Anthony Fauci announced in April 2020 that the ACTT results showed a clear benefit and said remdesivir would become a standard of care. The drug had previously performed poorly in a major Ebola treatment trial. None of that proves that its adoption for COVID was improper, but neither does it make criticism of the speed and enthusiasm with which it was incorporated into hospital protocols illegitimate.
Miller's account of the early wave also diverges sharply from the public picture he remembers being presented. He testified that his hospital's COVID surge peaked around March 17, 2020, and that it did not run out of beds, staff or equipment. He described sitting with colleagues at the nurses' station of an ICU that was about 30 percent occupied, with nurses being sent home for lack of patients, while a news report described their unit as overwhelmed. He also alleged that COVID became the default cause on some death certificates and that correcting it could be difficult. In one case, he said, an elderly dialysis patient was admitted with a brain bleed, eventually tested positive for COVID and died from the bleed, yet he was prevented from correcting the death certificate. Again, these are allegations made by Miller about what he witnessed. They are serious precisely because they are specific enough to be investigated rather than merely believed.
The financial incentives surrounding COVID treatment, by contrast, are not simply allegations. Congress created a 20 percent Medicare inpatient payment increase for qualifying COVID-19 admissions under the CARES Act. In November 2020, Medicare also introduced the New COVID-19 Treatments Add-on Payment, or NCTAP, providing additional reimbursement in qualifying cases involving authorised COVID treatments, including remdesivir. The precise reimbursement formula was more complicated than a simple "remdesivir bonus," and it would be wrong to infer from the existence of additional payments that hospitals deliberately made patients sicker for money. But the incentives existed, and it is legitimate to ask whether reimbursement rules influenced institutional preferences and discouraged departures from approved protocols.
That distinction matters. A financial incentive does not prove corrupt medical treatment. Nor does following a federally supported treatment protocol prove that a physician was putting money before a patient. What it does show is that treatment, reimbursement, liability and institutional policy became intertwined during the emergency. Cheap off-label treatments such as ivermectin did not receive the same NCTAP support. A physician considering departure from the approved institutional pathway was therefore not making a purely pharmacological decision. He or she could also be departing from the hospital's reimbursement, legal and administrative structure.
Families who appeared at the hearing described what they believed that structure meant at the bedside. Their allegations were strikingly similar. Patients were isolated. Some relatives testified that unvaccinated patients were spoken to with contempt or told that they were likely to die. Families said requests for ivermectin, hydroxychloroquine, vitamins or other treatments were refused. Several alleged that remdesivir was administered despite objections and that kidney problems followed. Others described pressure to accept ventilation or do-not-resuscitate orders. One witness alleged that access to a priest for last rites was made conditional on accepting remdesivir; another family said visitation was linked to changing their father's resuscitation status. There were allegations of inadequate food, water, hygiene and clothing. These accounts should be reported for what they are: testimony from patients and relatives, not adjudicated findings about American hospitals as a whole.
Getting a patient out of hospital could itself become a battle, according to witnesses. One husband described a six-hour confrontation involving police before he succeeded in taking his wife home, where she subsequently recovered. Other witnesses described court battles over ivermectin and attempts to get prohibited medication to relatives inside hospitals. An attorney who said she acted for 212 families testified that only three of 72 patients who obtained court-ordered ivermectin died, whereas all 140 patients who did not obtain it died. Those are extraordinary figures, but they are testimony, not a randomised controlled trial, and they cannot by themselves establish that ivermectin caused the difference. Patients who obtained court orders were not randomly assigned, and numerous selection effects and clinical differences could have separated the two groups. What the figures unquestionably demonstrate is the extraordinary degree to which disputes over treatment had moved from the bedside into the courtroom.
Miller chose another route. He opened a free clinic for unvaccinated patients. He says that decision, together with his resistance to prevailing protocols, contributed to his eventual exclusion from hospital surgery. Other clinicians appearing at the hearing described being fired, reported to medical boards, subjected to peer-review proceedings or otherwise professionally sanctioned after departing from institutional COVID policies. Pierre Kory and Paul Marik became nationally prominent examples of physicians whose disputes with mainstream COVID treatment policy ultimately separated them from their previous institutional roles. Whatever one thinks of the treatments they advocated, the broader question remains legitimate: how much clinical independence should a doctor retain when professional judgment conflicts with an institutionally mandated protocol?
That question has become more important because American physicians have increasingly moved from independent practice into employment by larger organisations. According to the American Medical Association, 60.1 percent of physicians worked in private practices in 2012; by 2024 the figure had fallen to 42.2 percent. That change cannot simply be blamed on the Affordable Care Act, since numerous economic and structural forces have driven consolidation. But it changes the balance of power. A physician who owns his practice can still suffer professional consequences for defying conventional medicine, but an employed physician who defies the treatment policy of the institution paying his salary faces an additional and immediate form of discipline.
This is the part that should trouble anyone who values independent medical judgment. COVID created conditions in which doctors had to make decisions amid uncertainty, frightened patients, rapidly changing evidence, government recommendations, institutional protocols, reimbursement rules and enormous professional pressure. Some conformity was unavoidable and some standardisation undoubtedly saved lives. But standardisation carries its own danger. Medicine ceases to be fully medical when the physician standing beside the bed is no longer permitted to exercise judgment about the particular human being lying in it.
Miller did not become a good doctor by being pushed out. By his account, the conflict arose because he already believed that the physician's primary obligation was to the individual patient rather than to the administrative machinery surrounding the patient. Whether every allegation he has made withstands independent investigation is a separate question. The importance of his testimony lies precisely in the fact that it raises questions that should be investigated rather than dismissed because their answers might embarrass institutions.
Something unquestionably happened to public confidence during this period. Between April 2020 and January 2024, the proportion of Americans reporting a great deal of trust in doctors and hospitals fell from 71.5 percent to 40.1 percent in a very large national study. The researchers also found that lower trust was associated with lower uptake of COVID vaccination and boosters. Their data do not establish that controversial hospital treatment caused the collapse in trust, and they do not establish that distrust caused vaccine refusal. But a fall of more than thirty percentage points in less than four years is itself a medical and social event requiring explanation.
Patients who believe that a parent was isolated, treated against the family's wishes, denied requested alternatives or pushed through an inflexible protocol are unlikely to have their confidence restored by another public-relations campaign. Some of their beliefs may prove mistaken; some allegations may be exaggerated; some treatments they demanded may not have worked. Medicine nevertheless has to confront those experiences rather than assuming that declining trust is merely another pathology of the patient.
The good doctor is not simply the doctor who rebels against protocol, any more than he is simply the doctor who follows it. He is the doctor whose first loyalty remains to the patient in front of him and who retains enough professional independence to say when the standard answer does not fit the particular case. James Miller's testimony raises an uncomfortable question about modern institutional medicine: if a doctor believes that obligation requires him to depart from the approved pathway, does the system still have room for him?
https://www.midwesterndoctor.com/p/how-hospitals-turned-on-their-patients
